NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (the “Company”) (NYSE Alternext US: PRW), today provided an update regarding the company’s proposed rights offering, pre-New Drug Application (NDA) filing and related meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s lead product candidate DAVANAT®, NYSE Alternext US stock listing, and cash saving initiatives.
